Adacel vaccine is indicated for active booster immunization for the prevention of tetanus, diphtheria, and pertussis as a single dose in persons 11 through 64 years of age.

The threat of pertussis may not be obvious to them.Thankfully, it’s obvious to you.

Page 1 of 6

Friends, Cousins, and Part-time Caretakers

Mother Father

Siblings

Aunts and Uncles

Grandparents

Sources of infant pertussis

Other

Family

Page 2 of 6

Please click here for Important Safety Information.

Family members are the primary source of pertussis in infants1

Studies show that when the source can be identified, family members are the source in

up to 83% of cases transmitted to infants1

International multicenter study of 91 families1

• Source cases were identified for 44 infants and described by relationship to the infant, age, and household status1

a CDC = Centers for Disease Control and Prevention. b Tdap = Tetanus, diphtheria, and acellular pertussis.

Infants under 6 months of age are most vulnerable to complications from pertussis2

Pediatricians play a vital role in helping to protect families against pertussis by:• Informing parents about the threat pertussis poses to families and the importance

of immunization with Tdap

• Continuing to immunize eligible adolescents ≥11 years of age with Adacel vaccine

Despite CDCa recommendations, only 8% of adults reported receiving Tdapb vaccine from 2005 through 2010.3,4

One shot. Big impact.

Adacel vaccine—the Tdap vaccine that shares your commitment

Adacel vaccine is dedicated to informing the public about the threat of pertussis to make your conversations with parents short and effective

• Adacel vaccine encourages parents to take an active role in pertussis prevention through a variety of channels, including:

For more information about Adacel vaccine and pertussis, please visit www.AdacelVaccine.com.

Please click here for Important Safety Information.

– Direct-to-patient communications

– Educational Web sites for parents

– Televised public service announcements

Page 3 of 6

With G.I.F.T., choosing Adacel vaccine helps extend pertussis protection

Adacel vaccine is committed to helping protect more families who can’t afford vaccination against pertussis.

For every 100 doses of Adacel vaccine sold, Sanofi Pasteur donates 1 dose to AmeriCares® for the immunization of uninsured mothers and family members across the United States. AmeriCares identifies public and community health facilities to receive the doses.

• The G.I.F.T. program began in September 2010 and will continue through May 31, 2013, adding to the 150,000 doses already donated

Please click here for G.I.F.T. program Terms and Conditions.

c Td = Tetanus and diphtheria.

Over 67 million doses supplied in the United States since licensure in 2005.5

Adacel vaccine provides extensive real-world, clinical experience for adult and adolescent pertussis vaccination in the United States

Adacel vaccine has demonstrated immunogenicity in clinical trials6

Adacel vaccine has a safety profile similar to Tdc vaccine6

• Serious adverse events were uncommon and comparable in frequency to Td vaccine6

• Injection site pain was common and more frequent in adolescents receiving Tdap compared with Td vaccine6

Page 4 of 6

Please click here for Important Safety Information.

For more information about Adacel vaccine and pertussis, please visit www.AdacelVaccine.com.

Please click here for Important Safety Information.

Thank you for your commitment to help protect families against pertussis

Speak to your Sanofi Pasteur sales representative about your Tdap vaccine needs. You may also order Adacel vaccine at VaccineShoppe.com® or call 1-800-VACCINE (1-800-822-2463).

One shot. Big impact.Page 5 of 6

Easy ways to implement Tdap in your practice

Here are a few simple suggestions for how to help ensure families and

vulnerable infants in your practice are protected against pertussis

Screen parents for Tdap immunization status during routine newborn or 1-month visits and use chart stickers to note the status in the baby’s file

Have the nurse ask parents about Tdap immunization status during appointment check-in or when checking infant’s weight and height

Place reminders near scales or the check-in desk that encourage adult contacts to seek Tdap immunization from their primary-care providers or pharmacists

Include the Vaccine Information Sheet for Tdap along with other educational materials in newborn visit packets

Display Tdap information brochures in waiting and examination rooms, and include Tdap information on your practice’s Web site

Ensure members of your staff are immunized with Tdap

Use WellConnect® to contact all parents of children under 12 months of age

Page 6 of 6

Sanofi PaSteur. Discovery Drive. Swiftwater, Pennsylvania 18370. www.sanofipasteur.us

MKt25096 © 2012 Sanofi Pasteur inc. 11/12 Printed in uSa

IMPORTANT SAFETY INFORMATION

INDICATION Adacel vaccine is indicated for active booster immunization for the prevention of tetanus, diphtheria, and pertussis as a single dose in persons 11 through 64 years of age.

SAFETY INFORMATION The most common local and systemic adverse reactions to Adacel vaccine include injection site pain, erythema, and swelling; headache, body ache, tiredness, and fever. Other adverse reactions may occur. A severe allergic reaction after a previous dose of Adacel vaccine or any other tetanus toxoid, diphtheria toxoid, or pertussis-containing vaccine, or to any component, or encephalopathy within 7 days of a previous dose of a pertussis-containing vaccine, is a contraindication.

The decision to give Adacel vaccine should be based on the potential benefits and risks; especially if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid; if progressive or unstable neurologic disorders exist; or if adverse events have occurred in temporal relation to receipt of pertussis-containing vaccine. Persons who experienced Arthus-type hypersensitivity reactions following a prior dose of tetanus toxoid-containing vaccine should not receive Adacel vaccine less than 10 years since the last dose of tetanus toxoid-containing vaccine. The tip caps of the prefilled syringes may contain natural rubber latex, which may cause allergic reactions in latex-sensitive individuals. Vaccination with Adacel vaccine may not protect all individuals.

Before administering Adacel vaccine, please click here for accompanying full Prescribing Information.

CPT®d Code: 90715d CPT = Current Procedural Terminology is a registered trademark of the American Medical Association.

Adacel vaccine is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.

References: 1. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007;26:293-299. 2. Centers for Disease Control and Prevention (CDC). Pertussis. In: Atkinson W, Wolfe C, Hamborsky J, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed. Washington, DC: Public Health Foundation; 2011:215-232. 3. CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR. 2006;55(RR-17):1-37. 4. CDC. Adult vaccination coverage—United States, 2010. MMWR. 2012;61(4):66-72. 5. Sanofi Pasteur Inc. Data on file (Adacel vaccine direct doses distributed), October 11, 2011. MKT24538. 6. Adacel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2012.